Concepedia

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival

Giovanni Ponti, Marco Manfredini, Stefano Greco, Giovanni Pellacani, Roberta Depenni, Aldo Tomasi, Monia Maccaferri, Stefano Cascinu

Anticancer Research · 2017 · 49 citations · 9 references

DOIFull text

Open access

Abstract

BRAF, NRAS and C-KIT melanomas constitute distinct clinico-pathological entities. BRAF-mutated melanoma benefit from both anti-BRAF and anti-MEK targeted therapies while triple-negative melanomas could benefit from novel anti-CTLA-4 and anti-PD-L1 immunotherapeutic approaches.

References

9

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.6K citations · Full text

Somatic Activation of KIT in Distinct Subtypes of Melanoma

John A. Curtin, Klaus J. Busam, Daniel Pinkel et al. · Journal of Clinical Oncology · 2006 · 1.6K citations · Full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

, , +7

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Jean‐Jacques Grob, Mayur M. Amonkar, Bogusława Karaszewska et al. · The Lancet Oncology · 2015 · 255 citations

, , +9

Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients

Kaori Sakaizawa, Atsuko Ashida, Aya Uchiyama et al. · Journal of Dermatological Science · 2015 · 118 citations

, , +10